Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Aebersold
Felix Aebersold, Herrliberg CH
| Patent application number | Description | Published |
|---|---|---|
| 20090262948 | HEARING AID AND METHOD FOR OPERATING A HEARING AID - The invention relates to a hearing aid comprising at least one signal processing device, at least one counter for detecting discreet events or operating processes, and at least one memory for storing the values or states of the counter, and the threshold values associated with each counter. The hearing aid is also provided with a signal transmitter that is actively connected to the signal processing device in such a way that the signal transmitter is activated when a threshold value of a counter is reached or exceeded. In this way, advantageously, any countable pre-defined events or operating processes can be used to establish and maintain the operating state of the hearing aid. An operating process can be, for example, the variation of a defined operating state of the hearing aid. If a predetermined threshold value is reached, i.e. the number of events reaches this threshold value, a corresponding signal can be triggered and produced by the signal transmitter. | 10-22-2009 |
Hans Aebersold, Bonstetten CH
| Patent application number | Description | Published |
|---|---|---|
| 20110043361 | HAZARD ALARM WITH A VARIABLE HOLDING REGION FOR A SUPPLY ELEMENT - A danger sensor ( | 02-24-2011 |
Julia Aebersold, Floyds Knobs, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20100016704 | METHOD AND SYSTEM FOR MONITORING A CONDITION OF AN EYE - A method, system, and computer-readable medium are provided which monitor a condition of an eye. The system includes a communication interface and a processor operably coupled to the communication interface. The communication interface is configured to receive an intraocular pressure measurement datum and a time datum associated with the time the intraocular pressure measurement was measured using an eye measurement system. The processor is configured to receive the intraocular pressure measurement datum and the time datum, to receive a dispensed amount datum associated with an amount of a drug administered to an eye of a user and a second time datum associated with the time the drug was administered, and to store the received intraocular pressure measurement datum, the received time datum, the received dispensed amount datum, and the received second time datum to monitor a condition of the eye. | 01-21-2010 |
Julia Aebersold, Floyd Knobs, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20100236341 | ACTIVELY COOLED VAPOR PRECONCENTRATOR - An analyte collection system device includes an active area that includes a plurality of perforations extending therethrough. The plurality of perforations are arranged to permit passage of an analyte fluid flow through the microscale plate. A heating element is provided for heating the active area, and a thermal distribution layer is disposed over at least a portion of the active area. For cooling the active area at or below an ambient temperature, an active cooler is provided. | 09-23-2010 |
Julia W. Aebersold, Floyds Knobs, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20080208065 | Perivascular pressure sensor and sensing system - An embodiment of the invention is an in-vivo blood pressure sensor device including a strain transducer and flexible biocompatible material that carries the strain transducer. The flexible biocompatible material is configured to encircle the outside of a blood vessel when surgically installed. A preferred embodiment in-vivo blood pressure sensor device of the invention includes a strain transducer carried by a flexible biocompatible ring that is configured to be surgically installed to encircle a blood vessel. The device also includes passive circuitry encased in biocompatible material for sensing strain in the strain transducer and for providing data to an external reader. The passive circuitry is also configured to be surgically installed in a subject. The device further includes a telemetry coil encased in biocompatible material and configured to be surgically installed in a subject, to receive power via inductive coupling to an external reader, to supply power to the passive circuitry and to act as an antenna for communications with an external reader. | 08-28-2008 |
Julia W. Aebersold, Floyds Knob, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20090188325 | MEMS Capacitive Bending and Axial Strain Sensor - A three-dimensional micro-electro-mechanical-systems (MEMS) capacitive bending and axial strain sensor capacitor is described. Two independent comb structures, incorporating suspended polysilicon interdigitated fingers, are fabricated simultaneously on a substrate that can displace independently of each other while attached to a substrate undergoing bending or axial deformation. A change in spacing between the interdigitated fingers will output a change in capacitance of the sensor and is the primary mode of operation of the device. On the bottom and to the end of each comb structure, a glass pad is attached to the comb structure to allow for ample surface area for affixing the sensor to a substrate. During fabrication, tethers are used to connect each comb structure to maintain equal spacing between the fingers before attachment to the substrate. After attachment, the tethers are broken to allow independent movement of each comb structure. | 07-30-2009 |
Rudolf Aebersold, Zurich CH
| Patent application number | Description | Published |
|---|---|---|
| 20100216180 | METHODS OF USING HALOGENATED PEPTIDES AS INTERNAL STANDARDS FOR LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY - Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry, and novel halogenated peptides useful for the same, are disclosed. In particular, methods of using halogenated peptides as internal standards in proteomic analyses, as well as methods of using halogenated peptides to conduct quality control assessments of and/or to calibrate liquid chromatography-mass spectrometry systems are disclosed. | 08-26-2010 |
| 20110065605 | METHOD FOR BIOMARKER AND DRUG-TARGET DISCOVERY FOR PROSTATE CANCER DIAGNOSIS AND TREATMENT AS WELL AS BIOMARKER ASSAYS DETERMINED THEREWITH - The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself. | 03-17-2011 |
Rudolf H. Aebersold, Mercer Island, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20090111195 | CHEMICAL REAGENTS AND METHODS FOR DETECTION AND QUANTIFICATION OF PROTEINS IN COMPLEX MIXTURES - The invention provides a reagent comprising an affinity tag, a detectable moiety, a linker, an isotope tag and a reactive group. The invention also provides methods of using a reagent of the invention. The methods can be used to label a polypeptide in a sample by contacting a sample with a reagent of the invention under conditions allowing the reactive group to bind to one or more polypeptides in the sample. The invention additionally provides methods of isolating, identifying and quantifying a polypeptide in a sample. The invention further provides methods of diagnosing a disease using a reagent of the invention. | 04-30-2009 |
| 20100196883 | ANDROGEN-REGULATED GENES AND USES FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE NEOPLASTIC CONDITIONS - The invention provides a method for diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual. The method involves (a) determining a level of RDC1 in a sample from the individual, and (b) comparing the level of RDC1 in the sample to a reference level of RDC1, wherein a level of RDC1 in the sample 2-fold or more higher than the reference level indicates the presence of, or susceptibility to, a prostate neoplastic condition in the individual. | 08-05-2010 |
| 20100267577 | Methods for high throughput and quantitative proteome analysis - The invention provides methods for identifying and quantifying polypeptides in a sample. The methods include the steps of labeling peptides in a polypeptide sample with an isotope tag; adding a plurality of peptide standards to the polypeptide sample, wherein the peptide standards are labeled with an isotopically distinct version of the isotope tag; resolving the labeled sample and standard peptides into a plurality of fractions; analyzing the resolved fractions using mass spectrometry; identifying an isotope-tagged sample peptide in an analyzed fraction; and determining the amount of the identified isotope-tagged sample peptide in the analyzed fraction by comparison to the amount of isotope tagged standard peptide in the same fraction. | 10-21-2010 |
Rudolf H. Aebersold, Zurich CH
| Patent application number | Description | Published |
|---|---|---|
| 20100279382 | COMPOSITIONS AND METHODS FOR QUANTIFICATION OF SERUM GLYCOPROTEINS - The invention provides compositions and methods for identifying and/or quantifying glycopolypeptides from human serum or plasma. The compositions and methods include a plurality of standard peptides containing glycosylation sites determined for human serum/plasma proteins. | 11-04-2010 |
Rudolph H. Aebersold, Zurich CH
| Patent application number | Description | Published |
|---|---|---|
| 20100222233 | AFFINITY CAPTURE OF PEPTIDES BY MICROARRAY AND RELATED METHODS - The invention provides methods of detecting polypeptides in a sample. The method can include the steps of cleaving polypeptides in a test sample to generate peptides; adding a predetermined amount of isotopically labeled peptide standards to the cleaved test sample, wherein the peptide standards correspond to peptides cleaved with the same reagent used to cleave the test sample; contacting the cleaved test sample containing peptide standards with an array of immobilized binding agents specific for the peptide standards; washing the array to remove unbound peptides, thereby retaining affinity captured sample peptides and standard peptides; analyzing the affinity captured peptides using mass spectrometry; and determining the presence of bound test peptides and standard peptides. The method can further include the step of quantifying the amount of the test peptides by comparing the ratio of test peptide to corresponding standard peptide. | 09-02-2010 |